Yawning is a physiological behavior, an emotional stereotypy that indicates the homeostatic process of the mechanisms regulating rhythms, such as sleeping/waking, hunger/satiety or mating/relaxation, generated by the diencephalon. As with all physiological behaviors, its deregulation reveals disorders. In daily practice, yawning as a symptom is generally neglected. That is why we propose a wide overview of yawning in diseases, its consequences and significance.

Keywords:
Yawning, Migraine, Stroke, Tic
1.
Walusinski O, Deputte BL: The phylogeny, ethology and nosology of yawning. Rev Neurol (Paris) 2004;160:1011–1021.
2.
Barbizet J: Yawning. J Neurol Neurosurg Psychiatry 1958;21:203–209.
3.
Baenninger R, Binkley S, Baenninger M: Field observations of yawning and activity in humans. Physiol Behav 1996;59:421–425.
4.
Daquin G, Micallef J, Blin O: Yawning. Sleep Med Rev 2001;5:299–312.
5.
Kita I, Yoshida Y, Nishino S: An activation of parvocellular oxytocinergic neurons in the paraventricular nucleus in oxytocin-induced yawning and penile erection. Neurosci Res 2006;4:269–275.
6.
Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH: Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 2005;314:310–319.
7.
Meige H, Feindel G: Les tics et leur traitement. Paris, Masson, 1902, p 633.
8.
Craig AD: Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol 2003;13:500–505.
9.
Craig AD: How do you feel – now ? The anterior insula and human awareness. Nature Rev Neurosci 2009;10:59–70.
10.
Mogilnicka E, Klimek V: Drugs affecting dopamine neurons and yawning behavior. Pharmacol Biochem Behav 1977;7:303–305.
11.
Colosimo C, Pontieri FE: Yawning in Parkinson’s disease. Neurology 1999;52:428.
12.
Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, Chen J, Wang S, Woods JH: Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl) 2007;193:159–170.
13.
Blin O, Masson G, Azulay JP, Fondarai J, Serratrice G: Apomorphine-induced blinking and yawning in healthy volunteers. Br J Clin Pharmacol 1990;30:769–773.
14.
Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G: Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 1991;14:91–95.
15.
Goren JL, Friedman JH: Yawning as an aura for an L-Dopa-induced ‘on’ in Parkinson’s disease. Neurology 1998;50:823.
16.
Dewey RB, Hutton JT, Lewitt PA, Factor SA: A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58:1385–1392.
17.
Kolls BJ, Stacy M: Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin Neuropharmacol 2006;29:292–301.
18.
Lal S: Apomorphine in the evaluation of dopaminergic function in man. Progr Neuro-psychopharmacol Biol Psych 1988;12:117–164.
19.
Lal S, Tesfaye Y, Thavundayil JX, Skorzewska A, Schwartz G: Effect of time-of-day on yawning response to apomorphine in normal subjects. Neuropsychobiology 2000;41:178–180.
20.
Lewitt PA, Ondo WG, Van Lunen B, Bottini PB: Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating ‘off’ episodes in advanced Parkinson disease. Clin Neuropharmacol 2009, Epub ahead of print.
21.
Benoit A, Caplier A: Hypovigilance analysis: open or closed eye or mouth? Blinking or yawning frequency? Advanced Video and Signal Based Surveillance. 2005:207–212.
22.
Evans EB: Yawning in pharyngeal obstruction. Br Med J 1978;1:443–444.
23.
Cameron OG: Visceral Sensory Neuroscience: Interoception. Oxford, Oxford University Press, 2002.
24.
Grover M, Drossman DA: Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am 2009;19:151–170.
25.
Sato-Suzuki I, Kita I, Seki Y, et al: Cortical arousal induced by microinjection of orexins into the paraventricular nucleus of the rat. Behav Brain Res 2002;128:169–177.
26.
Adamantidis A, de Lecea L: Sleep and metabolism: shared circuits, new connections. Trends Endocrinol Metab 2008;19:362–370.
27.
Cronin TG: Yawning: an early manifestation of vasovagal reflex. AJR Am J Roentgenol 1988;150:209.
28.
Graybiel A, Knepton J: Sopite syndrome: a sometimes sole manifestation of motion sickness. Aviat Space Environ Med 1976;47:873–882.
29.
Charcot JM: Leçons du mardi à La Salpêtrière. Paris, Lecrosnier & Babé, 1889.
30.
Beale MD, Murphree TM: Excessive yawning and SSRI therapy. Int J Neuropsychopharmacol 2000;3:275–276.
31.
Gutierrez-Alvarez AM: Do your patients suffer from excessive yawning? Acta Psychiat Scand 2007;115:80–81.
32.
Chen CH, Lu ML: Venlafaxine-induced excessive yawning. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:156–157.
33.
De Las Cuevas C, Sanz EJ: Duloxetine-induced excessive disturbing and disabling yawning. J Clin Psychopharmacol 2007;27:106–107.
34.
Harada KI: Paroxetine-induced excessive yawning. Psychiat Clin Neurosci 2006;60:260.
35.
Modell JG: Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration. J Clin Psychopharmacol 1989;9:63–65.
36.
Dourish CT, Cooper SJ: Neural basis of drug induced yawning; in Cooper SJ, Dourish CT (eds): Neurobiology of Stereotyped Behaviour. New York, Clarendon Press, 1990, pp 91–116.
37.
Urba-Holmgren R, Holmgren B, Rodriguez R, Gonzalez RM: Serotoninergic modulation of yawning. Pharmacol Biochem Behav 1979;11:371–372.
38.
Sommet A, Desplas M, Lapeyre-Mestre M, Montastruc JL: Drug-induced yawning: a review of the French pharmacovigilance database. Drug Saf 2007;30:327–331.
39.
Goldberg RL: Sustained yawning as a side effect of imipramine. Int J Psychiatry Med 1983–84;13:277–280.
40.
McLean JD, Forsythe RG, Kapkin IA: Unusual side effects of clomipramine associated with yawning. Can J Psychiatry 1983;28:569–570.
41.
Furukawa T: Yawning behavior for preclinical drug evaluation. Methods Find Exp Clin Pharmacol 1996;18:141–155.
42.
Mogilnicka E, Klimek V: Drugs affecting dopamine neurons and yawning behavior. Pharmacol Biochem Behav 1977;7:303–305.
43.
Evans SM, Griffiths RR: Caffeine withdrawal: a parametric analysis of caffeine dosing conditions. J Pharmacol Exp Ther 1999;289:285–294.
44.
Freye E, Levy J: Acute abstinence syndrome following abrupt cessation of long-term use of tramadol: a case study. Eur J Pain 2000;4:307–311.
45.
Freye E, Levy J: Constitutive opioid receptor activation: a prerequisite mechanism involved in acute opioid withdrawal. Addict Biol 2005;10:131–137.
46.
Gowing L, Ali R, White J: Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2004;4:CDO2025.
47.
Hiltunen AJ, Lafolie P, Martel J, Ottosson EC, Boreus LO, Beck O, Borg S, Hjemdahl P: Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients. Psychopharmacology (Berl) 1995;118:122–126.
48.
Lane JD, Phillips-Bute BG: Caffeine deprivation affects vigilance performance and mood. Physiol Behav 1998;65:171–175.
49.
Phillips-Bute BG, Lane JD: Caffeine withdrawal symptoms following brief caffeine deprivation Physiol Behav 1997;63:35–39.
50.
Ostrea EM Jr, Chavez CJ, Strauss ME: A study of factors that influence the severity of neonatal narcotic withdrawal. Addict Dis 1975;2:187–199.
51.
Robe LB, Gromisch DS, Iosub S: Symptoms of neonatal ethanol withdrawal. Curr Alcohol 1981;8:485–493.
52.
Blau JN: Migraine postdromes: symptoms after attacks. Cephalalgia 1991;11:229–231.
53.
Cerbo R, Barbanti P, Buzzi MG, et al: Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 1997;20:36–44.
54.
Del Bene E, Poggioni M: Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 1994;34:536–538.
55.
Jacome DE: Compulsive yawning as migraine premonitory symptom. Cephalalgia 2001;21:623–625.
56.
Jacome DE: Primary yawning headache. Cephalalgia 2001;2:697–699.
57.
Quintela E, Castillo J, Muñoz P, Pascual J: Premonitory and resolution symptoms in migraine: a prospective study in 100 unselected patients. Cephalalgia 2006;26:1051–1060.
58.
Blau JN, Engel HO: Premonitory and prodromal symptoms in cluster headache. Cephalalgia 1998;18:91–93.
59.
Schoonman GG, Evers DJ, Terwindt GM, van Dijk JG, Ferrari MD: The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia 2006;26:1209–1213.
60.
Cattaneo L, Cucurachi L, Chierici E, Pavesi G: Pathological yawning as a presenting symptom of brainstem ischaemia in two patients. J Neurol Neurosurg Psychiatry 2006;77:98–100.
61.
Singer OC, Humpich MC, Lanfermann H, Neumann-Haefelin T: Yawning in acute anterior circulation stroke. J Neurol Neurosurg Psychiatry 2007;78:1253–1254.
62.
Walusinski O: Yawning and stroke. Editorial commentaries. J Neurol Neurosurgery Psychiatry 2007;78:1166.
63.
Bauer G, Gerstenbrand F, Hengl W: Involuntary motor phenomena in the locked-in syndrome. J Neurol 1980;223:191–198.
64.
Bauer G, Prugger M, Rumpl E: Stimulus evoked oral automatisms in the locked-in syndrome. Arch Neurol 1982;39:435–436.
65.
Krasnianski M, Gaul C, Neudecker S, Behrmann C, Schlüter A, Winterholler M: Yawning despite trismus in a patient with locked-in syndrome caused by a thrombosed megadolichobasilar artery. Clin Neurol Neurosurg 2003;106:44–46.
66.
Billeth R, Jörgler E, Baumhackl U: Bilateral anterior operculum syndrome (in German). Nervenarzt 2000;71:651–654.
67.
Laurent-Vannier A, Fadda G, Laigle P, Dusser A, Leroy-Malherbe V: Syndrome de Foix Chavany Marie d’origine traumatique. Rev Neurol 1999;155:387–390.
68.
Arai K, Kita K, Komiyama A, Hirayama K, Saeki N, Nagao K: Progressive dysautonomia in hemangioblastoma in the region of the fourth ventricle (in Japanese). No To Shinkei 1986;38:195–200.
69.
Gschwend J: Yawning in a case with transsecting glioma of the pons (in German). Fortschr Neurol Psychiatr Grenzgeb 1977;45:652–655.
70.
Wong KY, Ngan KC, Sin VC, Lau WH: Sphenoidal sinus mucocoele and yawning after radiation treatment for nasopharyngeal carcinoma. Clinical Oncol (R Coll Radiol) 1997;9:415–417.
71.
Jurko MF, Andy OJ: Post-lesion yawning and thalamotomy site. Appl Neurophysiol 1975;38:73–79.
72.
Crosby L, Parsons LC: Clinical neurologic assessment tool: development and testing of an instrument to index neurologic status. Heart Lung 1989;18:121–129.
73.
Bateman DE: Neurological assessment of coma. J Neurol Neurosurgery Psychiatry 2001;71:113–117.
74.
Manish M, Veenu S: Persistent vegetative state. Neurology 2007;68:1635.
75.
Gilles de la Tourette G, Huet E, Guinon G: Contribution à l’étude des bâillements hystériques. Nouvelle Iconographie de la Salpêtrière. Paris, Lecrosnier & Babé, 1890, pp 97–119.
76.
de Wied D: Behavioral pharmacology of neuropeptides related to melanocortins and the neurohypophyseal hormones. Eur J Pharmacol 1999;375:1–11.
77.
Sato F, Aoki H, Nakamura K, Taguchi M, Aoki T, Yasuda N: Suppressive effects of chronic hyperprolactinemia on penile erection and yawning following administration of apomorphine to pituitary-transplanted rats. J Androl 1997;18:21–25.
78.
Jackson JH: Selected Writings of John Hughlings Jackson; in Taylor, J (ed): On Epilepsy and Epileptiform Convulsions. London, Basic Books, 1931.
79.
Medrano V, Selles-Galiana MF, Fernandez-Izquierdo S, Mallada-Frechin J, Díaz-González F, Piqueras-Rodríguez L: Yawning and temporal lobe epilepsy (in Spanish). Rev Neurol 2005;4:63–64.
80.
Muchnik S, Finkielman S, Semeniuk G, de Aguirre MI: Yawning and temporal lobe epilepsy (in Spanish). Medicina (B Aires) 2003;63:137–139.
81.
Muchnik S, Finkielman S, Semeniuk G, de Aguirre MI: Yawning (in Spanish). Medicina (B Aires) 2003;63:229–232.
82.
Tassinari CA, Gardella E, Meletti S, et al: The neuro-ethological interpretation of motor behaviours in ‘nocturnal-hyperkinetic-frontalseizures’: emergence of ‘innate’ motor behaviours and role of central pattern generators; in Beaumanoir A, Andermann F, Chauvel P, et al (eds): Frontal Seizures and Epilepsies in Children. Montrouge, Libbey Eurotext, 2003, pp 43–48.
83.
Yankovsky AE, Andermann F, Dubeau F: Post-ictal forceful yawning in a patient with nondominant hemisphere epilepsy. Epileptic Disord 2006;8:65–69.
84.
Goldie L, Green JM: Yawning and epilepsy. J Psychosomatic Res 1961;5:263–268.
85.
Gowers WR: Epilepsy and Other Chronic Convulsive Diseases: Their Causes, Symptoms and Treatment. New York, Willam Wood and Co., 1885.
86.
Penfield W, Jasper H: Epilepsy and the Functional Anatomy of the Human Brain. Boston, Little, Brown & Co., 1954.
87.
Symonds CP: Discussion on faints and fits. Proc Royal Soc Med 1950;43:507–518.
88.
Andy OJ, Jurko M: Diencephalic seizures. Appl Neurophysiol 1983;46:62–67.
89.
Boeve BF, Wijdicks EF, Benarroch EE, Schmidt KD: Paroxysmal sympathetic storms (‘diencephalic seizures’) after severe diffuse axonal head injury. Mayo Clin Proc 1998;73:148–152.
90.
Bullard DE: Diencephalic seizures: responsiveness to bromocriptine and morphine. Ann Neurol 1987;21:609–611.
91.
Giroud M, Sautreaux JL, Thierry A, Dumas R: Diencephalic epilepsy with congenital suprasellar arachnoid cyst in an infant. Childs Nerv Syst 1988;4:252–254.
92.
Goh KY, Conway EJ, Da Rosso RC, Muszynski CA, Epstein FJ: Sympathetic storms in a child with a midbrain glioma: a variant of diencephalic seizures. Pediatr Neurol 1999;21:742–744.
93.
D’Mello DA, Vincent FM, Lerner MP: Yawning as a complication of electroconvulsive therapy and concurrent neuroleptic withdrawal. J Nerv Ment Dis 1988;176:188–189.
94.
Lum LM, Connolly MB, Farrell K, Wong PK: Hyperventilation-induced high-amplitude rhythmic slowing with altered awareness: a video-EEG comparison with absence seizures. Epilepsia 2002;43:1372–1378.
95.
Lafleur J, Reiher J: Pseudo-absences. Electroencephalogr Clin Neurophysiol 1977;43:279–280.
96.
Bidat E, Sznajder M, Fermanian C, et al: A diagnostic questionnaire for the hyperventilation syndrome in children (in French). Rev Mal Respir 2008;25:829–838.
97.
Klein DF: False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993;50:306–317.
98.
Nardi AE, Freire RC, Zin WA: Panic disorder and control of breathing. Respir Physiol Neurobiol 2009;167:133–143.
99.
Philippot P, Chapelle G, Blairy S: Respiratory feedback in the generation of emotion. Cogn Emot 2002;16:605–627.
100.
Saper CB: The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu Rev Neurosci 2002;25:433–469.
101.
Brown RP, Gerbarg PL: Sudarshan Kriya Yogic breathing in the treatment of stress, anxiety and depression: part I-neurophysiologic model. J Alternat Complement Med 2005;11:189–201.
102.
Gallezzo SR: Examining the connection between yawning and depression 2006. http://baillement.com/recherche/gallezzo.html.
103.
Greco M, Baenninger R: On the context of yawning: when, where and why? Psychol Rec 1993;43:175–183.
104.
Beckmann H, Zimmer R: An ethological interpretation of stereotypy induced by environmental stimulus. Arch Psychiatr Nervenkr 1981;230:81–89.
105.
Marcus N: Yawning: analytic and therapeutic considerations. Int J Child Psychother 1973;2:406–418.
106.
Shilkret H: Psychogenic sneezing and yawning. Psychosom Med 1949;11:127–128.
107.
Sandyk R: Excessive yawning and progressive supranuclear palsy. Int J Neurosci 1987;34:123–124.
108.
Louwerse E: Forced yawning as a pseudobulbar sign in amyotrophic lateral sclerosis. J Neurosci Res 1998;54suppl:392.
109.
Wicks P: Excessive yawning is common in the bulbar-onset form of ALS. Acta Psychiatr Scand 2007;116:76.
110.
Postert T, Pöhlau D, Meves S, Nastos I, Przuntek H: Pathological yawning as a symptom of multiple sclerosis. J Neurol 1996;243:300–301.
111.
von Economo C: Encephalitis Lethargica, Its Sequellae and Treatment. London, Oxford University Press, 1931.
112.
Sicard JA, Paraff A: Fou rire syncopal et bâillements au cours de l’encéphalite épidémique. Bull Mém Soc Méd Hôp Paris 1921;45:232.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.